Natrol S&E
This article was originally published in The Tan Sheet
Executive Summary
Revenues during the firm's second quarter grew 17.8 % to $19.5 mil., fueled by the strong performance of new the products which more than offset a decline from the discontinuation of Ester-C, the Chatsworth, Calif.-based firm says. The nutritional products company adds it is well-positioned to enter the international marketplace, and is benefiting from the diversification of its business through the recent acquisition of MRI (1"The Tan Sheet" June 18, 2007, p. 7). Operating income jumped 172.9% during the quarter to $737,000 while net income was $4.2 mil. compared to $100,000 in the year-ago period, the firm notes...
You may also be interested in...
Natrol Pumps Up In Sports Nutrition Market With MRI Acquisition
Dietary supplement manufacturer Natrol expands its sports nutrition product offerings with its $8 million cash acquisition of Medical Research Institute
Lilly Looks To Accelerate Tirzepatide Into Obesity With Rolling Submission
Plan for rolling submission means US FDA filing of GIP/GLP1 agonist in obesity could be complete by April 2023, setting up possibility of late 2023 approval.
EU To Expand Fragrance Allergen Labeling With Implications For California’s ‘Right To Know’
Companies will have more fragrance allergens to report to California health authorities if the European Union requires more than 50 additional fragrance allergens to be labeled on cosmetic products, as proposed by the Commission in September.